Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next
- 1 April 2020
- journal article
- review article
- Published by Elsevier in Brain Research
- Vol. 1732, 146683
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 158 references indexed in Scilit:
- Cellular and molecular mechanisms underlying muscular dystrophyJournal of Cell Biology, 2013
- Yunis-Varón Syndrome Is Caused by Mutations in FIG4, Encoding a Phosphoinositide PhosphataseThe American Journal of Human Genetics, 2013
- Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteinsProceedings of the National Academy of Sciences, 2011
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMNNature Biotechnology, 2010
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitorsProceedings of the National Academy of Sciences, 2008
- Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4JNature, 2007
- Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutationsJournal of Cell Biology, 2007
- Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMDGene Therapy, 2006